Health knowledge made personal
WellPage for Avastin Retina Vein Occlusion
+ Bookmark › Share
Go
Search posts:

Avastin Retina Vein Occlusion - Articles

Avastin/Lucentis Update 40: Lucentis is Approved for Treating Macular Edema in Retinal Vein Occlusion by Irv Arons Healthy Living Professional Posted Wed 23 Jun 2010 2:04pm According to an announcement from Genentech, Lucentis has been approved by the FDA for treating macular edema following retinal vein occlusion (RVO) Here is Genentech’s news release : FDA Approves Genentech's Lucentis (Ranibizumab Injection) for the Treatment of Macular Edema Following Retinal Vein Occlusion Ge ... Read on »
Retina 2007 Subspecialty Meeting Presentations – Day Two by Irv Arons Healthy Living Professional Posted Fri 26 Sep 2008 5:17pm Again, using briefs supplied by Ophthalmology Times and Ocular Surgery News, here are the highlights from the second day of the Retina 2007 Subspecialty Day presentations. First, here are the reports from the special session held at the end of the day, wherein Dr. Susan Desmond-Hellmann, president of product development for Genentech, spoke ... Read on »
Menu -- Part 10: Retinal Reports from the 2007 AAO Meeting by Irv Arons Healthy Living Professional Posted Fri 26 Sep 2008 5:17pm During the 2007 American Academy of Ophthalmology (AAO) Meeting, and the Subspecialty Days preceding it, especially Retina 2007, I received briefs about the meetings from both Ophthalmology Times and Ocular Surgery News. Using these briefs, I was able to prepare comprehensive writeups of both the two-day Retina 2007 presentations and retinal high ... Read on »
Avastin/Lucentis Update 43: Secret Rebates Offered for Lucentis by Irv Arons Healthy Living Professional Posted Thu 04 Nov 2010 3:12pm First, Genentech refused to provide Lucentis for the CATT Study, being run by NEI/NIH to compare Avastin to Lucentis for AMD ( Avastin/Lucentis Update 12 ); then they threatened to stop supplying Avastin to compounding pharmacies so that ophthalmologists could continue to obtain the drug for their patients ( Avastin/Lucentis Update 18 ); then the ... Read on »
More News from the 2007 AAO – Day Three by Irv Arons Healthy Living Professional Posted Fri 26 Sep 2008 5:17pm Again, using briefs supplied by Ophthalmology Times and Ocular Surgery News, here are some additional highlights from the Retina 2007 Subspecialty Day, and retinal treatment highlights from the opening day of the main 2007 AAO Meeting, being held in New Orleans. First, more from Retina 2007: Lucentis shown to reduce macular thickness more ... Read on »
Iluvien and the Future of Ophthalmic Drug Delivery Systems by Irv Arons Healthy Living Professional Posted Tue 27 Jul 2010 10:50am I was recently sent a news release from Alimera Sciences, who have filed an NDA requesting priority review for its Iluvien sustained release drug delivery system for treating diabetic macula edema, which if granted could result in an action letter granting approval for marketing before the end of this year. This got me thinking that I ... Read on »
Menu 17: Updates for June – September 2010 by Irv Arons Healthy Living Professional Posted Wed 06 Oct 2010 9:19am June through September turned out to be busier than anticipated. A number of new technologies emerged that I decided to write about. Included in these were a new sustained release drug delivery system, Iluvien; the use of lasers to treat eye floaters – in both the U.S. and in Europe; the idea of using femtosecond lasers to postpone the need for c ... Read on »
Retinal Vein Occlusion by EyeDrD Posted Tue 14 Jun 2011 8:04am ← Vietnam and U.S. will hold joint navy exercise New Chinese Imperialism in Angola → Read on »
Eye Injections of Avastin Linked to Infections by EyeDrD Posted Mon 05 Sep 2011 11:58am Commentary: The recent waves of eye infections, endophthalmitis, after eye injections of Avastin to treat the blinding condition of wet macular degeneration , have caused safety concerns of Avastin. Repackaging or compounding the drug seems to be the source of infection. ... Read on »
Avastin/Lucentis Update 27: Dr. Rosenfeld’s Remarks at Retina Congress 2009 by Irv Arons Healthy Living Professional Posted Mon 05 Oct 2009 10:00pm The following abstract of Dr. Rosenfeld’s remarks were reported by OSN Supersite in their continuing coverage of Retina Congress 2009. Search for optimal anti-VEGF dosing strategy in AMD continues Although the optimal dosing of anti-VEGF therapy remains unknown, pharmacokinetics of the two most popular agents suggest that adjusting the cur ... Read on »